Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Slain

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Pharmacotherapy|April 30, 1999
Lipid-based amphotericin B for the treatment of fungal infectionsD Slain
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2001
Intermittent antimycobacterial dosage correctionD Slain
The Annals of Pharmacotherapy|June 21, 2001
Intravenous itraconazoleD Slain, P D Rogers, J D Cleary, et al.
Pharmacotherapy|August 12, 2000
Variability in activity of hepatic CYP3A4 in patients infected with HIVD Slain, A Pakyz, D S Israel, et al.
Journal of Clinical Pharmacology|April 18, 2001
Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjectsB M Sadler, G E Chittick, R E Polk, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Pharmacotherapy|April 30, 1999
Lipid-based amphotericin B for the treatment of fungal infectionsD Slain
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2001
Intermittent antimycobacterial dosage correctionD Slain
The Annals of Pharmacotherapy|June 21, 2001
Intravenous itraconazoleD Slain, P D Rogers, J D Cleary, et al.
Pharmacotherapy|August 12, 2000
Variability in activity of hepatic CYP3A4 in patients infected with HIVD Slain, A Pakyz, D S Israel, et al.
Journal of Clinical Pharmacology|April 18, 2001
Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjectsB M Sadler, G E Chittick, R E Polk, et al.
Pageof 1